DIVISLAB Share Price Target 2023, 2024, 2025 to 2030: Can it touch 5000 INR in 2023?

Divi’s Laboratories (NSE: DIVISLAB), a leading Indian pharmaceutical firm, has a major focus on the development, production, and marketing of active pharmaceutical ingredients (APIs) and intermediates. The business has a history of steady growth and profitability, and over the past ten years, it has been one of the best-performing stocks on the Indian market. With a market valuation of more than Rs. ₹ 92,489 Crore as of November 7, 2023, Divi’s Laboratories’ share price has been circling about Rs. 3,484 per share.

We will discuss the share price targets for Divi’s Laboratories during the subsequent 7–10 years, from 2023 to 2030 in this article. To determine whether Divi’s Labs is a solid investment, we will examine the company’s financial performance, growth potential, competitive environment, and industry trends.

How to buy Divi’s Laboratories shares?

You can buy Divi’s Laboratories shares from the following trading platforms:

➤ Zerodha

➤ Upstox

➤ Groww

➤ AngelOne

➤ ICICIDirect

Share Price Prediction of Divi’s Laboratories: 2023 to 2030

Share Price Target 2023 of Divi’s Laboratories

In November 2023, Divi’s Laboratories is expected to see its share price range between a maximum of ₹3,762.72 and a minimum of ₹3,271.93. The forecast for December 2023 suggests that the share price may rise further, with an estimated maximum of ₹3,886.89 and a minimum of ₹3,379.90. These projections indicate potential upward movement in the company’s stock.

As of now, the current share price stands at ₹3,484, and the company’s market capitalization is ₹92,489 crore. Investors and analysts will closely monitor these price targets to assess the performance and growth potential of Divi’s Laboratories in the coming months.

Share Price Target 2024 of Divi’s Laboratories

In 2024, Divi’s Laboratories is poised for a potentially strong performance in the stock market, based on the projected share price targets. In January, the share price is estimated to reach a maximum of ₹3,966.21 and a minimum of ₹3,448.88, with consistent growth expected throughout the year.

By December 2024, the share price is anticipated to reach a maximum of ₹4,535.69 and a minimum of ₹3,944.08. These forecasts suggest a positive outlook for Divi’s Laboratories, with potential for significant value appreciation. Investors and stakeholders will closely monitor the company’s performance in line with these projections, which could indicate a promising year ahead.

Share Price Target 2025 of Divi’s Laboratories

In 2025, Divi’s Laboratories appears to be on a trajectory of strong growth and potential value appreciation, as indicated by the projected share price targets. In January 2025, the estimated share price range is between a maximum of ₹4,626.40 and a minimum of ₹3,558.77, showcasing a significant upward trend. This positive momentum continues throughout the year, with December 2025 projections reaching a maximum of ₹5,529.64 and a minimum of ₹4,253.57. These forecasts suggest a bullish sentiment surrounding the company, with the share price expected to exhibit consistent growth over the course of the year.

Investors and market observers will be keenly monitoring Divi’s Laboratories as it progresses through 2025.

Divi’s Laboratories Share Price Target: 2026-2030

The share price targets for Divi’s Laboratories for the period spanning 2026 to 2030 suggest a continued and potentially substantial upward trajectory. In 2026, the estimated share price is projected to reach a maximum of ₹5,806.12 and a minimum of ₹4,064.28, reflecting a positive outlook for the company’s growth potential. As we move into 2027, the price targets become even more optimistic, with a maximum of ₹6,386.73 and a minimum of ₹4,470.71.

The year 2028 stands out with a significant projected range, indicating a remarkable surge in value. The share price is forecasted to reach a maximum of ₹8,941.43, with a minimum of ₹4,470.71. The subsequent years, 2029 and 2030, maintain strong growth expectations, with substantial ranges. In 2029, the share price is estimated to fluctuate between a maximum of ₹7,741.50 and a minimum of ₹3,870.75, while in 2030, it is expected to reach an impressive maximum of ₹10,063.94, with a minimum of ₹7,044.76.

These projections illustrate an exciting growth trajectory for Divi’s Laboratories, suggesting robust market demand, successful product performance, and favorable industry conditions.

Financial Condition of Divi’s Laboratories: Last 5 years

Over the past five years, Divi’s Laboratories has experienced consistent growth, as evidenced by its financial statements. The company’s revenue has increased steadily from ₹3,891.49 crores in March 2018 to ₹7,768 crores in March 2023, indicating an impressive revenue growth of approximately 100%.

During the same period, Divi’s Laboratories’ net profit has also shown an upward trend, with a maximum net profit of ₹2,960.45 crores in March 2022, a significant increase from the minimum net profit of ₹877.01 crores in March 2018. Divislab’s net profit in 2023 however has declined to ₹1,823 Crore, slightly below what the company reported in FY ending 2021.

Excluding 2023, upto 2022, the percentage growth in net profit has been equally remarkable, with a growth of over 100% in the four years.

Also, Divi’s Laboratories’ operating profit margin (OPM) has also been consistently high, indicating the company’s efficient operations. The OPM has steadily increased from 32.61% in March 2018 to 43.36% in March 2022 and 30% in March 2023, indicating high profit margin.

Divi’s Laboratories has also maintained an impressive dividend payout ratio, with a range of 26.76% to 31.40% over the past five years. The company’s earnings per share (EPS) has also shown a steady increase, from ₹33.03 in March 2018 to ₹111.50 in March 2022.

In conclusion, Divi’s Laboratories has shown consistent growth in revenue, profit, and operational efficiency over the past five years.

Divi’s Laboratories share price target by Experts

Divi’s Laboratories share price target by Religare Broking

FAQS

Will the share price of Divi’s Laboratories increase in 2023?

It is anticipated that Divi’s Laboratories per share price will increase to ₹3,886.89 by the end of 2023.

What is the share price target of Divi’s Laboratories for 2025?

The share price target of Divi’s Laboratories for 2025 might be around ₹5,529.64.

Is Divi’s Laboratories free from all debts?

Yes, Divi’s Laboratories is a stock that has no debt and has the potential to grow significantly, resulting in investors becoming millionaires over an extended period.

What is the share price target of Divi’s Laboratories for 2030?

The per share price of Divi’s Laboratories might reach around ₹10,063.94 by the end of 2030.

Can we consider Divi’s Laboratories as a large-cap stock?

Yes, Divi’s Laboratories Ltd, established in 1990, is a company operating in the pharmaceutical sector with a market capitalization of Rs ₹ 92,489 Crore, making it a Large Cap company.

Also read:

• Coal India Share Price Target 2023 to 2030: Can it touch 300 INR in 2023?
• Power Grid Share Price Target 2023 to 2030: Can it reach 1000 INR by 2030?
• JK Tyre and Industries Share Price Target 2023 to 2030: Can it touch 500 INR?

Conclusion: Should You Invest in Divi’s laboratories?

Well, one thing so good about Divis Laboratories is its profit margin, which has been above 30% quarter on quarter for quite some time now. Divi’s Laboratories is also one of the favorite stocks of Saurabh Mukherjee. Let’s look at the PE ratio of the company to decide whether DIVISLABS is overvalued or undervalued.

Divislabs PE ratio

Looking at the Divislabs PE ratio, we can say, around January, February was a good time to accumulate Divis Labs when the PE ratio was around 30, and in comparison, PE ratio is around 55. The median PE is 46.4. We are definitely trading above the median PE, and hence the stock is overvalued. 

I would wait for the stock to correct by 20-25% before taking a position in Divislab. Sales and Profit has reduced for the last 4 quarters.

With an anticipated growth rate of 15% annually, the company’s share price objective for the years 2023 to 2030 appears to be on the right track. Divi’s shares may appear pricey with a market valuation of 99967 crore and a price-to-earnings ratio of 55, but they have high long-term growth potential. Thus, Divi’s Laboratories may be a suitable option for investors seeking a solid stock in the pharmaceutical industry.

Author: Neha BhardwajHello, I am Neha. I am currently pursuing B.Sc (Hons.) Computer Science from Hansraj College, University of Delhi. I am skilled in web content writing and my interest lies in the field of Data Analytics, Finance and Marketing.